Elafibranor 80 mg
Sponsors
Genfit, Ipsen
Conditions
Primary Biliary Cholangitis (PBC)Primary Sclerosing Cholangitis
Phase 2
Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid
CompletedNCT03124108
Start: 2017-04-05End: 2018-10-31Updated: 2019-09-24
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
Active, not recruitingNCT05627362
Start: 2022-12-29End: 2031-09-23Updated: 2026-08-31